Glenmark Pharmaceuticals has completed the third phase of human trials of Crofelemer, a new drug to treat HIV-related diarrhoea that could rake in over $80 million. The company has the right to launch the product in 140 countries, excluding the US, Europe, Japan and China, where its partners have marketing rights, Glenmark said in a statement.
In the US and the Europe, Salix Pharmaceuticals has the rights to sell the drug while in Japan and China, Luye Pharmaceuticals has the rights to sell the product, which is the first of its type. Glenmark is the sole global supplier of its active pharmaceutical ingredient (API) to Salix Pharmaceuticals, except in China. Indian drugmakers have mastered developing low cost version of off-patent drugs and Crofelemer would be the country’s first new drug, if it is successfully launched.
crackcrack| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: